Table 3.
Characteristics of patients diagnosed with high-risk (HR) neuroblastoma.
| No | Age [Years], Sex | ECOG Status | Treatment (Number of Cycles) | Previous Lines of Therapy | Effect of Treatment | Adverse Events (CTCAE Grade) |
|---|---|---|---|---|---|---|
| 1 | 12.3/F | 1 | NIVO (13) + DB | 4 | CR (OS = 18 months) | Pneumonia (2) |
| 2 | 10.2/M | 1 | NIVO (16) + DB | 1 | CR (OS = 7.9 months) | None |
| 3 | 10.5/M | 0 | NIVO (6) | 4 | PD | None |
| 4 | 3.2/M | 4 | NIVO (2) + DB | 2 | PD | None |
| 5 | 5.6/M | 4 | NIVO (3) + DB | 2 | PD | None |
| 6 | 7.0/M | 2 | NIVO (3) | 3 | PD | None |
| 7 | 3.7/M | 4 | NIVO (2) | 2 | PD | None |
| 8 | 3.2/F | 4 | NIVO (2) + DB | 2 | PD | None |
| CUMULATIVE | Median age: 6.3 years (M = 6; F = 2) | Poor general condition (ECOG ≤ 2) in 5/8 patients | Median ICIs doses: 3 | Median: 2 | CR in two patients | Good tolerance of therapy in all patients |
F: female; M: male; NIVO: nivolumab; DB: dinutuximab beta; ICIs: immune checkpoint inhibitors; CR: complete remission; OS: overall survival; PD: progressive disease.